Articles From: Enanta Pharmaceuticals Announces 96 Percent SVR12 in Treatment Experienced Genotype 1 Hepatitis C Patients in SAPPHIRE-II Study to Enbridge Energy Partners and Enbridge Energy Management File Annual Report on Form 10-K


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced results from the SAPPHIRE-II study, the second of six phase 3 registrational studies being conducted by AbbVie for the treatment of hepatitis C virus (HCV) genotype 1 (GT1) infection, using a regimen containing Enanta’s lead protease inhibitor ABT-450.
Sign-up for Enanta Pharmaceuticals Announces 96 Percent SVR12 in Treatment Experienced Genotype 1 Hepatitis C Patients in SAPPHIRE-II Study investment picks
2014/3/24
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced eight studies have been accepted for presentation at the International Liver Congress (ILC), which is the 49th Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in London April 9-12, 2014.
Sign-up for Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the European Association for the Study of the Liver (EASL) Meeting investment picks
2014/4/11
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that detailed results from AbbVie’s pivotal phase 3 SAPPHIRE-I study, will be presented today at the International Liver Congress (ILC), which is the 49th Annual Meeting of the European Association for the Study of the Liver (EASL) and featured in the ILC press conference.
Sign-up for Enanta Pharmaceuticals Announces Detailed Data from SAPPHIRE-I and SAPPHIRE-II Phase 3 Studies in Patients with Chronic Hepatitis C Virus Being Presented at the European Association for the Study of the Liver (EASL) Meeting investment picks
2014/4/12
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that detailed results from AbbVie’s pivotal phase 3 TURQUOISE-II study, will be presented as a late-breaking oral presentation today at the International Liver Congress (ILC), which is the 49th Annual Meeting of the European Association for the Study of the Liver (EASL). Results from the TURQUOISE-II study were featured in the ILC press conference yesterday and were published on-line in the New England Journal of Medicine .
Sign-up for Enanta Pharmaceuticals Announces Detailed Data from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis being Presented at the European Association for the Study of the Liver (EASL) Meeting investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), has agreed to provide additional funding of $9.2 million to its existing contract with Enanta to fund preclinical and early clinical development for a new class of bridged bicyclic antibiotics known as Bicyclolides.
Sign-up for Enanta Pharmaceuticals Announces National Institute of Allergy and Infectious Diseases (NIAID) Will Fund Further Development of a Novel Bicyclolide investment picks
2014/3/4
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that new in vitro data on ABT-493, a potent NS3/4 protease inhibitor, was presented today during a poster session at the 21 st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
Sign-up for Enanta Pharmaceuticals Announces New Data Presented on Protease Inhibitor ABT-493 at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) investment picks
2014/1/31
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced results from the PEARL-II, PEARL-III, PEARL-IV and TURQUOISE-II studies.
Sign-up for Enanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus Infection investment picks
2013/11/25
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the appointment of Bruce L.A. Carter, Ph.D. to its Board of Directors.
Sign-up for Enanta Pharmaceuticals Announces the Appointment of Bruce L.A. Carter, Ph.D. to Board of Directors investment picks
2014/2/11
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the appointment of George S.
Sign-up for Enanta Pharmaceuticals Announces the Appointment of George S. Golumbeski, Ph.D. to Board of Directors investment picks
2014/2/3
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the appointment of Timothy D.
Sign-up for Enanta Pharmaceuticals Announces the Appointment of Timothy D. Ocain, Ph.D. as Senior Vice President, New Product Strategy and Development investment picks
2014/1/13
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the initiation of a Phase 1 clinical study of EDP-788, Enanta’s investigational compound for MRSA (methicillin-resistant Staphylococcus aureus ) infections.
Sign-up for Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported financial results for its fiscal first quarter ended December 31, 2013.
Sign-up for Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2013 investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported financial results for its fiscal fourth quarter and year ended September 30, 2013.
Sign-up for Enanta Pharmaceuticals Reports Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2013 investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported financial results for its third fiscal quarter and nine months ended June 30, 2013.
Sign-up for Enanta Pharmaceuticals Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended June 30, 2013 investment picks
2013/11/15
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that it plans to report its fiscal fourth quarter and September 30 year end financial results before the U.S. markets open on November 25, 2013.
Sign-up for Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2013 investment picks
2013/11/6
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R.
Sign-up for Enanta Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference investment picks
2014/2/6
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R.
Sign-up for Enanta Pharmaceuticals to Present at the 2014 Leerink Global Healthcare Conference Presentation to be Webcast on February 13, 2014 at 2:15 P.M. ET investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R.
Sign-up for Enanta Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference investment picks
2014/2/21
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R.
Sign-up for Enanta Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R.
Sign-up for Enanta Pharmaceuticals to Present at the Deutsche Bank 2013 BioFest investment picks
2013/8/28
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Enanta management will present at two investor conferences during the month of September.
Sign-up for Enanta Pharmaceuticals to Present at Upcoming Investor Conferences investment picks
2013/7/25
ADVISORY, July 25, 2013 (GLOBE NEWSWIRE) -- What: Enanta Pharmaceuticals, Inc., (Nasdaq:ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, will celebrate their recent initial public offering and recognize World Hepatitis Day (July 28) by visiting the NASDAQ MarketSite in Times Square on July 26.
Sign-up for Enanta Pharmaceuticals, Inc. [ENTA] Celebrates Their Recent IPO and Recognizes World Hepatitis Day by Ringing The NASDAQ Stock Market Opening Bell investment picks
http://media.marketwire.com/attachments/201201/10226_EnbridgeLogoforNewsReleases2012.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1050788&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Management Announces Closing of Public Offering of Listed Shares investment picks
http://media.marketwire.com/attachments/201201/10226_EnbridgeLogoforNewsReleases2012.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1053713&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Management Announces Closing of Underwriters' Option to Purchase Additional Listed Shares investment picks
http://media.marketwire.com/attachments/201201/10226_EnbridgeLogoforNewsReleases2012.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1049189&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Management Announces Public Offering of Listed Shares investment picks
http://media.marketwire.com/attachments/201201/10226_EnbridgeLogoforNewsReleases2012.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1049381&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Management Prices Offering of Listed Shares investment picks
2014/2/5
http://media.marketwire.com/attachments/201201/10226_EnbridgeLogoforNewsReleases2012.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1087670&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Management, L.L.C. Confirms Amount of Share Distribution for Fourth Quarter 2013 investment picks
2013/8/6
http://media.marketwire.com/attachments/201201/10226_EnbridgeLogoforNewsReleases2012.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1040410&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Management, L.L.C. Confirms Amount of Share Distribution for Second Quarter 2013 investment picks
2013/11/6
http://media.marketwire.com/attachments/201201/10226_EnbridgeLogoforNewsReleases2012.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1065918&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Management, L.L.C. Confirms Amount of Share Distribution for Third Quarter 2013 investment picks
2014/2/18
http://media.marketwire.com/attachments/201201/10226_EnbridgeLogoforNewsReleases2012.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1090769&ProfileId=051205&sourceType=1 HOUSTON, TX --
Sign-up for Enbridge Energy Partners and Enbridge Energy Management File Annual Report on Form 10-K investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Enanta Pharmaceuticals Announces 96 Percent SVR12 in Treatment Experienced Genotype 1 Hepatitis C Patients in SAPPHIRE-II Study to Enbridge Energy Partners and Enbridge Energy Management File Annual Report on Form 10-K
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity